Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12051948 | 0.81 | KDM4E (0.34) | KDM4ENPC1HPGDMAPK1RAB9A | |
| SCHEMBL12052008 | 0.79 | — | — | |
| SCHEMBL12052003 | 0.73 | KDM4E (0.38) | KDM4ENPC1HPGDMAPK1RAB9A | |
| SCHEMBL12052004 | 0.72 | KDM4E (0.37) | KDM4ENPC1HPGDMAPK1RAB9A | |
| SCHEMBL12051998 | 0.69 | KDM4E (0.34) | KDM4ENPC1HPGDMAPK1RAB9A | |
| SCHEMBL12052828 | 0.69 | RAB9A (0.37) | KDM4ENPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL12052802 | 0.69 | ACACB (0.34) | KDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL12051962 | 0.66 | KDM4E (0.31) | KDM4EHPGD | |
| SCHEMBL12051952 | 0.64 | KDM4E (0.49) | KDM4ENPC1HPGDMAPK1RAB9A | |
| SCHEMBL13550167 | 0.64 | KDM4E (0.34) | KDM4ENPC1HPGDMAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076330-B2 | Dipeptidyl peptidase-IV inhibitors | AMGEN INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20110112051-A1 | Dipeptidyl Peptidase-IV Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112051-A1 | Dipeptidyl Peptidase-IV Inhibitors | DPP4, DPP3, DPP7 | KDM4E 465/4885NPC1 1571/4885HPGD 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.